Key Takeaways
- Shares of Aethlon Medical jumped more than 471% during premarket hours on September 17, 2026, following merger news with North Immunology
- The transaction will establish a newly combined Nasdaq-traded entity named North Immunology, Inc. with ticker symbol NRTX
- Post-merger ownership will see North Immunology stakeholders and PIPE participants controlling approximately 95% of shares, while Aethlon investors retain about 4.75%
- Major healthcare investment firms, including Bain Capital Life Sciences and Janus Henderson, contributed to an oversubscribed $180 million financing round expected to support operations through late 2028
- The company’s primary therapeutic candidate NOR-101, targeting atopic dermatitis with a bispecific antibody approach, is scheduled for Phase 1a clinical trials in early 2027
Shares of Aethlon Medical (AEMD) skyrocketed more than 471% during Thursday’s premarket session following the announcement of a definitive all-stock merger deal with private biotech firm North Immunology.
Disclosed on September 17, 2026, the transaction will merge both entities through their wholly owned acquisition vehicles Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC.
Following completion, the merged organization will operate as North Immunology, Inc. and trade on the Nasdaq Capital Market using ticker NRTX.
According to the merger structure, North Immunology’s current shareholders combined with incoming PIPE financing participants will control roughly 95.25% of the post-transaction company.
Current Aethlon’s stockholders will retain approximately 4.75% ownership in the new organization, supplemented by contingent value rights linked to potential monetization of Aethlon’s existing Hemopurifier technology.
Accompanying the merger announcement is an oversubscribed $180 million private investment in public equity (PIPE), demonstrating robust institutional backing for the transaction.
The financing round attracted prominent healthcare investment entities including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, Farallon Capital Management, Adage Capital Partners LP, and TCGX.
Within the $180 million total, roughly $34 million represents conversion of North Immunology’s existing convertible promissory notes, alongside accumulated interest, premiums, and associated fees.
The capital raised is projected to sustain the combined entity’s operational requirements through the latter half of 2028.
North Immunology’s Drug Development Pipeline
North Immunology specializes in developing bispecific antibody therapeutics designed to address inflammatory mechanisms underlying immune-mediated disorders.
The company’s flagship program, NOR-101, represents a half-life extended IL-13 x IL-18 bispecific antibody specifically designed for treating atopic dermatitis.
NOR-101 Development Roadmap
Initial Phase 1a clinical testing of NOR-101 is slated to commence during Q1 2027, with preliminary pharmacokinetic and safety results anticipated around mid-2027.
Management intends to launch both Phase 1b and Phase 2b atopic dermatitis trials during 2027.
Primary outcome data from these clinical studies is projected for release in 2028.
The merger transaction is anticipated to finalize during Q1 2027, subject to obtaining shareholder consent, regulatory clearances, and exchange listing approval.
North Immunology’s current leadership team and board members will assume control of the combined business upon transaction completion.
According to TipRanks data, the latest analyst consensus on AEMD stock stands at Hold with a $1.50 price target.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
